Sign In
3 Nov 2008 08:26
|
Immediate Release
|
3 November 2008
|
ABCAM PLC
("Abcam" or "the Company")
AGM Statement
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is holding its Annual General Meeting for shareholders at 10.00 am this morning. At the meeting, the Chairman David Cleevely will make the following statement.
"I am pleased to report that trading for the 2009 financial year has started well and the Company has traded ahead of our expectations for the first four months of the year. Demand for our products has been strong and we continue to see growth across all regions. Trading has also benefitted from the weakness in sterling.
"As shareholders will appreciate, the threat of global recession and the volatility in the currency markets represent major risks for all businesses including our own. We believe however the demand from centrally funded research will provide significant resilience for our revenues. Overall, your board remains cautiously optimistic for the remainder of our financial year."
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7776 1500
Nominated Adviser Michael Meade/ Nick Westlake
Corporate Broking James Black
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 46,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs approximately 184 staff in its three operating companies
Follow the stocks
